Topic
Topic
Dupilumab produced positive outcomes in patients with skin of color, according to a real-world study covered in Managed Healthcare Executive, addressing a long-standing trial diversity gap in atopic…
A JID study from Indiana University identifies IGFL1 and IGFL4 as IL-4/IL-13–responsive amplifiers in atopic dermatitis, mapping…
Pfizer's tilrekimig produced Phase II skin clearance in atopic dermatitis and is positioned for a direct head-to-head against dup…
Dupilumab was tied to lower atopic march risk than topical corticosteroids in children, per Contemporary Pediatrics. The signal r…
Phase 3 results from 412 Chinese patients show oturkibart, an IL-4Rα monoclonal antibody, drove 74.5% of participants to a 4-poin…
Three-year extension data show nemolizumab sustains response in adults with moderate-to-severe atopic dermatitis, according to co…
Dupilumab-treated patients show more oral food challenge reactions despite lower food-specific IgE, new findings reported by Meds…
Pfizer has detailed Phase II data for its investigational atopic dermatitis candidate, setting up a direct mid-stage challenge to…
Sanofi has signed a new $8 billion pact with Regeneron, extending the alliance behind Dupixent and signaling further investment i…
Sanofi will pay Regeneron $1 billion up front plus up to $7 billion in milestones to co-develop four long-acting antibodies targe…